Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Adcetris brentuximab vedotin: Interim Phase II data

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Adcetris brentuximab vedotin (SGN-35) Business: Cancer Molecular target: CD30 Description: Antibody-…

    Published on 1/26/2015
  • Adcetris brentuximab vedotin: Preliminary Phase II data

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Adcetris brentuximab vedotin (SGN-35) Business: Cancer Molecular target: CD30 Description: Antibody-…

    Published on 1/26/2015
  • Anagrelide CR: Preliminary Phase II data

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: Anagrelide CR (GALE-401) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide Indication: Treat …

    Published on 1/26/2015
  • Aramchol arachidyl amino cholanoic acid: Clinical trial data

    Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), Tel Aviv, Israel Product: Aramchol arachidyl amino cholanoic acid Business: Hepatic Molecular target: Stearoyl-CoA desaturase-1 (SCD1) Description: Synthetic conjugate of …

    Published on 1/26/2015
  • Bavituximab: Phase II data

    Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), Tustin, Calif. Product: Bavituximab (3G4) Business: Cancer Molecular target: Phosphatidylserine Description: Chimeric mAb against phosphatidylserine Indication: Treat …

    Published on 1/26/2015
  • E2006: Phase II data

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: E2006 Business: Neurology Molecular target: Orexin 1 receptor (HCRTR1) (OX1R); Orexin 2 receptor (HCRTR2) (OX2R) Description: Dual orexin receptor antagonist Indication…

    Published on 1/26/2015
  • Egalet-001: Clinical trial data

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Product: Egalet-001 Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1) Description: Abuse-deterrent, extended-release, oral formulation of morphine Indication: …

    Published on 1/26/2015
  • Enzalutamide: Phase II data

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Enzalutamide (Xtandi) (formerly MDV3100) Business: Cancer Molecular target: Androgen receptor Description: …

    Published on 1/26/2015
  • Halaven eribulin mesylate: Phase II data

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Halaven eribulin mesylate (E7389) Business: Cancer Molecular target: Tubulin polymerase Description: Synthetic analog of halichondrin B Indication: Treat metastatic …

    Published on 1/26/2015
  • Lyrica pregabalin CR: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Lyrica pregabalin CR Business: Neurology Molecular target: GABA receptor Description: Controlled-release formulation of pregabalin, a GABA receptor agonist Indication: …

    Published on 1/26/2015
  • Masitinib: Phase II data

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 1/26/2015
  • Mipsagargin: Phase II data

    GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Product: Mipsagargin (G-202) Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Prodrug of plant-derived cytotoxin …

    Published on 1/26/2015
  • NW-3509: Additional Phase I data

    Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Product: NW-3509 Business: Neurology Molecular target: Sodium channel Description: Voltage-gated sodium channel inhibitor Indication: Treat schizophrenia Endpoint:…

    Published on 1/26/2015
  • ProHema: Interim Phase II data

    Fate Therapeutics Inc. (NASDAQ:FATE), San Diego, Calif. Product: ProHema Business: Cancer Molecular target: NA Description: Hematopoietic stem cells modulated with FT1050, a small molecule prostaglandin E2 analog …

    Published on 1/26/2015
  • Ricolinostat: Additional Phase Ib data

    Acetylon Pharmaceuticals Inc., Boston, Mass. Product: Ricolinostat (ACY-1215) Business: Cancer Molecular target: Histone deacetylase 6 (HDAC6) Description: Oral histone deacetylase 6 (HDAC6) inhibitor Indication: Treat …

    Published on 1/26/2015
  • Ricolinostat: Additional Phase I/II data

    Acetylon Pharmaceuticals Inc., Boston, Mass. Product: Ricolinostat (ACY-1215) Business: Cancer Molecular target: Histone deacetylase 6 (HDAC6) Description: Oral histone deacetylase 6 (HDAC6) inhibitor Indication: Treat …

    Published on 1/26/2015
  • Sacituzumab govitecan: Additional Phase I/II data

    Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Sacituzumab govitecan (hRS7-SN-38) (IMMU-132) Business: Cancer Molecular target: Epithelial glycoprotein-1 (EGP-1) Description: Humanized antibody against …

    Published on 1/26/2015
  • SGN-CD33A: Interim Phase I data

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Product: SGN-CD33A Business: Cancer Molecular target: CD33 Description: Humanized mAb against CD33 conjugated to 2 pyrrolobenzodiazepine (PBD) dimer moieties …

    Published on 1/26/2015
  • SNS01-T: Additional Phase Ib/IIa data

    Sevion Therapeutics Inc. (OTCQB:SVON), Bridgewater, N.J. Product: SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01, a compound …

    Published on 1/26/2015
  • SYN-004: Phase Ia data

    Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: SYN-004 (formerly P3A) Business: Infectious Molecular target: NA Description: Second-generation, oral beta lactamase (LACTB) that binds with and neutralizes…

    Published on 1/26/2015
  • TGR-1202: Additional Phase I/II data

    Rhizen Pharmaceuticals S.A., La Chaux-de-Fonds, Switzerland TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: TGR-1202 (formerly RP5264) Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) …

    Published on 1/26/2015
  • Ublituximab: Additional Phase I/II data

    LFB S.A., Les Ulis, France TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Ublituximab (TGTX-1101, TG-1101, LFB-R603) Business: Cancer …

    Published on 1/26/2015
  • Vaxchora: Phase III data

    PaxVax Inc., Redwood City, Calif. Product: Vaxchora (PXVX0200) Business: Infectious Molecular target: NA Description: Live attenuated vaccine against Vibrio cholerae Indication: Prevent cholera infection Endpoint: …

    Published on 1/26/2015
  • VR475: Phase IIb/III data

    Vectura Group plc (LSE:VEC), Chippenham, U.K. Product: VR475 Business: Inflammation Molecular target: NA Description: Inhaled formulation of the corticosteroid budesonide delivered with Vecturas Akita Jet smart …

    Published on 1/26/2015
  • VT-122HCC: Phase II data

    Vicus Therapeutics LLC, Morristown, N.J. Product: VT-122HCC Business: Inflammation Molecular target: Adrenergic receptor beta (ADRB); Cyclooxygenase-2 (COX-2) Description: Fixed-dose combination of propranolol, a non-…

    Published on 1/26/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993